Morgan Stanley Maintains Equal-Weight on Artivion, Lowers Price Target to $16
Morgan Stanley analyst Cecilia Furlong maintains Artivion (NYSE:AORT) with a Equal-Weight and lowers the price target from $23 to $16.
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers
Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today
Artivion (NYSE:AORT) has outperformed the market over the past 20 years by 1.64% on an annualized basis producing an average annual return of 9.19%. Currently, Artivion has a market capitalization of $608.77 million.
Artivion Stock Plunges Apixaban Vs. Warfarin Trial Setback, Reaffirms Annual Guidance
Artivion Inc (NYSE:AORT) has stopped the PROACT Xa trial to determine if patients with an On-X mechanical aortic valve can be…
Artivion Follows Recommendation To Stop PROACT Xa Clinical Trial
Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to
Lake Street Initiates Coverage On Artivion with Buy Rating, Announces Price Target of $32
Lake Street analyst Frank Takkinen initiates coverage on Artivion (NYSE:AORT) with a Buy rating and announces Price Target of $32.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
Morgan Stanley Maintains Equal-Weight on Artivion, Lowers Price Target to $21
Morgan Stanley analyst Cecilia Furlong maintains Artivion (NYSE:AORT) with a Equal-Weight and lowers the price target from $23 to $21.